NLSP
NLS Pharmaceutics AG
NLS Pharmaceutics AG (NLSP) is currently in a downtrend, trading below both the 50-day and 200-day moving averages. RSI is at 19.7 (oversold), with 0/3 trend checks passing.
NLSP with MA50 and MA200
Key levels & signals
NLSP valuation multiples (TTM)
NLS Pharmaceutics AG (NLSP) currently looks weaker on the chart and is not showing much trend strength. The latest available price is $2.91, and 0 of 3 core trend checks are currently passing. Price is trading below the 50-day moving average by 60.1% and below the 200-day moving average by 60.6%.
NLSP currently has an RSI reading of 19.7, which places it in a deeply oversold zone. That can sometimes lead to bounce-watch setups, but it can also reflect genuine weakness, so the chart still needs proper confirmation rather than hope alone.
For traders reviewing NLSP next, the main question is whether weakness is starting to stabilise or whether the chart still looks vulnerable to further downside. Some traders may watch for bounce attempts, but others will want to see stronger proof that the trend is improving before treating the stock as a cleaner setup.
About NLS Pharmaceutics AG
NLS Pharmaceutics AG is a biopharmaceutical firm dedicated to researching and creating treatments for intricate and uncommon conditions affecting the central nervous system. Its primary focus includes advancing medications for narcolepsy, idiopathic hypersomnia, and various other unusual sleep conditions, alongside neurodevelopmental challenges like attention deficit hyperactivity disorder (ADHD). Key experimental compounds in its pipeline are Quilience, designed to address excessive daytime sleepiness and cataplexy, and Nolazol, which targets ADHD. Established in 2015, the company maintains its headquarters in Zurich, Switzerland.
NLSP shares outstanding over time
Tracking total shares outstanding is one way to spot dilution — a rising line means the company has issued more shares (stock-based compensation, secondary offerings, convertible debt), which spreads the same earnings and ownership across more shares. A falling line usually reflects buybacks.
Learn the indicators behind this page
More stock opportunities
Common questions about NLSP
Is this page a buy or sell recommendation?
No. This page is designed to help you review chart structure, momentum and technical context more quickly, but it is not personal financial advice.
Why can a stock look bullish and overbought at the same time?
Strong trending stocks can still become stretched in the short term. That is why trend traders and dip buyers can read the same chart differently.
What should I do next after reading this page?
Open the full dashboard, review the chart in more detail, compare indicators, and decide whether the setup still makes sense within your own process.